Jazz Pharmaceuticals plc (JAZZ)
JAZZ Stock Price Chart
Explore Jazz Pharmaceuticals plc interactive price chart. Choose custom timeframes to analyze JAZZ price movements and trends.
JAZZ Company Profile
Discover essential business fundamentals and corporate details for Jazz Pharmaceuticals plc (JAZZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jun 2007
Employees
2.80K
Website
https://www.jazzpharma.comCEO
Bruce C. Cozadd
Description
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ Financial Timeline
Browse a chronological timeline of Jazz Pharmaceuticals plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $5.85, while revenue estimate is $1.11B.
Earnings released on 5 Aug 2025
EPS came in at -$8.25 falling short of the estimated -$6.12 by -34.80%, while revenue for the quarter reached $1.05B , missing expectations by -0.14%.
Earnings released on 6 May 2025
EPS came in at $1.68 falling short of the estimated $4.51 by -62.75%, while revenue for the quarter reached $897.84M , missing expectations by -15.68%.
Earnings released on 25 Feb 2025
EPS came in at $6.60 surpassing the estimated $5.83 by +13.21%, while revenue for the quarter reached $1.09B , beating expectations by +10.48%.
Earnings released on 6 Nov 2024
EPS came in at $6.61 surpassing the estimated $5.47 by +20.84%, while revenue for the quarter reached $1.05B , missing expectations by -0.18%.
Earnings released on 31 Jul 2024
EPS came in at $5.30 surpassing the estimated $4.68 by +13.25%, while revenue for the quarter reached $1.02B , missing expectations by -1.34%.
Earnings released on 1 May 2024
EPS came in at $2.68 falling short of the estimated $4.14 by -35.27%, while revenue for the quarter reached $901.98M , missing expectations by -5.45%.
Earnings released on 28 Feb 2024
EPS came in at $5.02 falling short of the estimated $5.26 by -4.56%, while revenue for the quarter reached $1.01B , beating expectations by +5.71%.
Earnings released on 8 Nov 2023
EPS came in at $4.84 falling short of the estimated $4.90 by -1.22%, while revenue for the quarter reached $972.14M , missing expectations by -3.63%.
Earnings released on 9 Aug 2023
EPS came in at $4.51 surpassing the estimated $4.46 by +1.12%, while revenue for the quarter reached $957.32M , beating expectations by +1.53%.
Earnings released on 10 May 2023
EPS came in at $3.95 falling short of the estimated $4.26 by -7.28%, while revenue for the quarter reached $892.81M , missing expectations by -5.42%.
Earnings released on 1 Mar 2023
EPS came in at -$0.07 falling short of the estimated $0.51 by -113.73%, while revenue for the quarter reached $972.12M , beating expectations by +8.57%.
Earnings released on 9 Nov 2022
EPS came in at $5.17 surpassing the estimated $4.72 by +9.53%, while revenue for the quarter reached $940.65M , beating expectations by +0.07%.
Earnings released on 3 Aug 2022
EPS came in at $4.30 surpassing the estimated $4.20 by +2.38%, while revenue for the quarter reached $932.88M , beating expectations by +3.37%.
Earnings released on 4 May 2022
EPS came in at $3.73 falling short of the estimated $3.75 by -0.53%, while revenue for the quarter reached $813.72M , missing expectations by -4.54%.
Earnings released on 1 Mar 2022
EPS came in at $4.21 surpassing the estimated $3.71 by +13.48%, while revenue for the quarter reached $896.73M , beating expectations by +3.75%.
Earnings released on 9 Nov 2021
EPS came in at $4.20 surpassing the estimated $3.27 by +28.44%, while revenue for the quarter reached $838.12M , beating expectations by +0.39%.
Earnings released on 3 Aug 2021
EPS came in at $3.90 surpassing the estimated $3.55 by +9.86%, while revenue for the quarter reached $751.81M , meeting expectations.
Earnings released on 4 May 2021
EPS came in at $3.92 surpassing the estimated $3.69 by +6.23%, while revenue for the quarter reached $607.58M , missing expectations by -0.52%.
Earnings released on 23 Feb 2021
EPS came in at $4.00 falling short of the estimated $4.10 by -2.44%, while revenue for the quarter reached $665.52M , beating expectations by +4.13%.
Earnings released on 2 Nov 2020
EPS came in at $4.31 surpassing the estimated $4.03 by +6.95%, while revenue for the quarter reached $600.89M , beating expectations by +5.97%.
JAZZ Stock Performance
Access detailed JAZZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.